Optimizing antigen selection for the development of tuberculosis vaccines
Tuberculosis (TB) remains a prevalent global infectious disease caused by genetically closely related tubercle bacilli in Mycobacterium tuberculosis complex (MTBC). For a century, the Bacillus Calmette-Guérin (BCG) vaccine has been the primary preventive measure against TB. While it effectively prot...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-06-01
|
| Series: | Cell Insight |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S277289272400018X |
| _version_ | 1797242885277483008 |
|---|---|
| author | Yang Yang Yi-Zhen Chen Tian Xia |
| author_facet | Yang Yang Yi-Zhen Chen Tian Xia |
| author_sort | Yang Yang |
| collection | DOAJ |
| description | Tuberculosis (TB) remains a prevalent global infectious disease caused by genetically closely related tubercle bacilli in Mycobacterium tuberculosis complex (MTBC). For a century, the Bacillus Calmette-Guérin (BCG) vaccine has been the primary preventive measure against TB. While it effectively protects against extrapulmonary forms of pediatric TB, it lacks consistent efficacy in providing protection against pulmonary TB in adults. Consequently, the exploration and development of novel TB vaccines, capable of providing broad protection to populations, have consistently constituted a prominent area of interest in medical research. This article presents a concise overview of the novel TB vaccines currently undergoing clinical trials, discussing their classification, protective efficacy, immunogenicity, advantages, and limitations. In vaccine development, the careful selection of antigens that can induce strong and diverse specific immune responses is essential. Therefore, we have summarized the molecular characteristics, biological function, immunogenicity, and relevant studies associated with the chosen antigens for TB vaccines. These insights gained from vaccines and immunogenic proteins will inform the development of novel mycobacterial vaccines, particularly mRNA vaccines, for effective TB control. |
| first_indexed | 2024-04-24T18:46:20Z |
| format | Article |
| id | doaj.art-6c11fbf7829b49bf9ade1ec6b7845fa1 |
| institution | Directory Open Access Journal |
| issn | 2772-8927 |
| language | English |
| last_indexed | 2024-04-24T18:46:20Z |
| publishDate | 2024-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cell Insight |
| spelling | doaj.art-6c11fbf7829b49bf9ade1ec6b7845fa12024-03-27T04:53:19ZengElsevierCell Insight2772-89272024-06-0133100163Optimizing antigen selection for the development of tuberculosis vaccinesYang Yang0Yi-Zhen Chen1Tian Xia2State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, 730000, ChinaState Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, 730000, ChinaState Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, 730000, China; Gansu Province Research Center for Basic Disciplines of Pathogen Biology, Lanzhou, 730046, China; Corresponding author. State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, 730000, China.Tuberculosis (TB) remains a prevalent global infectious disease caused by genetically closely related tubercle bacilli in Mycobacterium tuberculosis complex (MTBC). For a century, the Bacillus Calmette-Guérin (BCG) vaccine has been the primary preventive measure against TB. While it effectively protects against extrapulmonary forms of pediatric TB, it lacks consistent efficacy in providing protection against pulmonary TB in adults. Consequently, the exploration and development of novel TB vaccines, capable of providing broad protection to populations, have consistently constituted a prominent area of interest in medical research. This article presents a concise overview of the novel TB vaccines currently undergoing clinical trials, discussing their classification, protective efficacy, immunogenicity, advantages, and limitations. In vaccine development, the careful selection of antigens that can induce strong and diverse specific immune responses is essential. Therefore, we have summarized the molecular characteristics, biological function, immunogenicity, and relevant studies associated with the chosen antigens for TB vaccines. These insights gained from vaccines and immunogenic proteins will inform the development of novel mycobacterial vaccines, particularly mRNA vaccines, for effective TB control.http://www.sciencedirect.com/science/article/pii/S277289272400018XTuberculosisVaccineAntigen selectionImmunogenicity |
| spellingShingle | Yang Yang Yi-Zhen Chen Tian Xia Optimizing antigen selection for the development of tuberculosis vaccines Cell Insight Tuberculosis Vaccine Antigen selection Immunogenicity |
| title | Optimizing antigen selection for the development of tuberculosis vaccines |
| title_full | Optimizing antigen selection for the development of tuberculosis vaccines |
| title_fullStr | Optimizing antigen selection for the development of tuberculosis vaccines |
| title_full_unstemmed | Optimizing antigen selection for the development of tuberculosis vaccines |
| title_short | Optimizing antigen selection for the development of tuberculosis vaccines |
| title_sort | optimizing antigen selection for the development of tuberculosis vaccines |
| topic | Tuberculosis Vaccine Antigen selection Immunogenicity |
| url | http://www.sciencedirect.com/science/article/pii/S277289272400018X |
| work_keys_str_mv | AT yangyang optimizingantigenselectionforthedevelopmentoftuberculosisvaccines AT yizhenchen optimizingantigenselectionforthedevelopmentoftuberculosisvaccines AT tianxia optimizingantigenselectionforthedevelopmentoftuberculosisvaccines |